ARL6IP6

Summary

ARL6IP6 (ARF like GTPase 6 interacting protein 6, HGNC:24048) is a protein-coding gene on chromosome 2q23.3, encoding ADP-ribosylation factor-like protein 6-interacting protein 6 (Q8N6S5).

Predicted to be located in nuclear inner membrane.

Source: NCBI Gene 151188 — RefSeq curated summary.

At a glance

• Gene–disease (curated): cutis marmorata telangiectatica congenita (Limited, GenCC)
• GWAS associations: 4
• Clinical variants (ClinVar): 48 total — 1 likely-pathogenic
• Phenotypes (HPO): 32
• MANE Select transcript: NM_152522

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24048
Approved symbol	ARL6IP6
Name	ARF like GTPase 6 interacting protein 6
Location	2q23.3
Locus type	gene with protein product
Status	Approved
Aliases	MGC33864
Ensembl gene	ENSG00000177917
Ensembl biotype	protein_coding
OMIM	616495
Entrez	151188

Gene structure

Transcript identifiers

Ensembl transcripts: 23 — 11 protein_coding, 5 retained_intron, 4 nonsense_mediated_decay, 3 protein_coding_CDS_not_defined

ENST00000326446, ENST00000425034, ENST00000455875, ENST00000463690, ENST00000495469, ENST00000685752, ENST00000686080, ENST00000686839, ENST00000686951, ENST00000687504, ENST00000688012, ENST00000688130, ENST00000688171, ENST00000688293, ENST00000689155, ENST00000690119, ENST00000690703, ENST00000690727, ENST00000691523, ENST00000691702, ENST00000692124, ENST00000692399, ENST00000693573

RefSeq mRNA: 3 — MANE Select: NM_152522 NM_001350068, NM_001371972, NM_152522

CCDS: CCDS2197, CCDS92880

Canonical transcript exons

ENST00000326446 — 4 exons

Exon	Start	End
ENSE00001288604	152759747	152762396
ENSE00001288614	152718620	152719024
ENSE00003467576	152734994	152735126
ENSE00003493000	152720533	152720586

Expression profiles

Bgee: expression breadth ubiquitous, 253 present calls, max score 98.15.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 39.1533 / max 315.5645, expressed in 1819 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
23103	33.5838	1817
23102	3.5545	1565
23101	1.4207	744
23105	0.3048	86
23104	0.2895	111

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	98.15	gold quality
ganglionic eminence	UBERON:0004023	97.63	gold quality
germinal epithelium of ovary	UBERON:0001304	96.51	gold quality
trabecular bone tissue	UBERON:0002483	95.67	gold quality
placenta	UBERON:0001987	94.67	gold quality
epithelial cell of pancreas	CL:0000083	94.53	gold quality
skin of hip	UBERON:0001554	94.12	gold quality
palpebral conjunctiva	UBERON:0001812	94.03	gold quality
upper leg skin	UBERON:0004262	94.01	gold quality
oral cavity	UBERON:0000167	93.39	gold quality
parietal pleura	UBERON:0002400	92.59	gold quality
bronchial epithelial cell	CL:0002328	92.39	gold quality
oviduct epithelium	UBERON:0004804	92.39	gold quality
bone marrow	UBERON:0002371	92.27	gold quality
mammalian vulva	UBERON:0000997	92.22	gold quality
mucosa of sigmoid colon	UBERON:0004993	91.98	gold quality
epithelium of nasopharynx	UBERON:0001951	91.82	gold quality
bronchus	UBERON:0002185	91.82	gold quality
visceral pleura	UBERON:0002401	91.75	gold quality
colonic mucosa	UBERON:0000317	91.63	gold quality
superficial temporal artery	UBERON:0001614	91.49	gold quality
adult organism	UBERON:0007023	91.19	gold quality
thymus	UBERON:0002370	91.10	gold quality
jejunal mucosa	UBERON:0000399	91.05	gold quality
tibia	UBERON:0000979	90.93	gold quality
mucosa of paranasal sinus	UBERON:0005030	90.83	gold quality
seminal vesicle	UBERON:0000998	90.74	gold quality
lower lobe of lung	UBERON:0008949	90.68	gold quality
monocyte	CL:0000576	90.57	gold quality
esophagus squamous epithelium	UBERON:0006920	90.51	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-5	yes	20.95
E-MTAB-7381	no	224.81
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

128 targeting ARL6IP6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515

Literature-anchored findings (GeneRIF, showing 1)

• ARL6IP6 as a novel candidate gene for a syndromic form of CMTC. (PMID:25957586)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	arl6ip6	ENSDARG00000071013
mus_musculus	Arl6ip6	ENSMUSG00000026960
rattus_norvegicus	Arl6ip6	ENSRNOG00000005074

Protein

Protein identifiers

ADP-ribosylation factor-like protein 6-interacting protein 6 — Q8N6S5 (reviewed: Q8N6S5)

Alternative names: Phosphonoformate immuno-associated protein 1

All UniProt accessions (9): Q8N6S5, A0A8I5KQ30, A0A8I5KQY4, A0A8I5KRB3, A0A8I5KU55, A0A8I5KYK3, A0A8I5QJ95, H7C0H7, H7C192

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Nucleus inner membrane.

Similarity. Belongs to the ARL6IP6 family.

RefSeq proteins (3): NP_001336997, NP_001358901, NP_689735* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029383	ARL6IP6	Family

Pfam: PF15062

UniProt features (13 total): modified residue 5, transmembrane region 3, region of interest 2, chain 1, sequence conflict 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N6S5-F1	56.77	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 65, 80, 2, 36, 60

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 232 (showing top): HORIUCHI_WTAP_TARGETS_DN, FISCHER_G1_S_CELL_CYCLE, LFA1_Q6, CMYB_01, HNF4_01, DODD_NASOPHARYNGEAL_CARCINOMA_UP, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, FISCHER_DREAM_TARGETS, ZHANG_BREAST_CANCER_PROGENITORS_UP, RGAGGAARY_PU1_Q6, GOCC_NUCLEAR_ENVELOPE, NUYTTEN_EZH2_TARGETS_DN, GOCC_ORGANELLE_INNER_MEMBRANE, MARSON_BOUND_BY_FOXP3_STIMULATED, MARSON_BOUND_BY_FOXP3_UNSTIMULATED

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): nuclear inner membrane (GO:0005637), nucleus (GO:0005634), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
organelle inner membrane	1
nuclear membrane	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

374 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARL6IP6	FMNL2	Q96PY5	646
ARL6IP6	RFTN2	Q52LD8	552
ARL6IP6	PLBD2	Q8NHP8	518
ARL6IP6	MED29	Q9NX70	485
ARL6IP6	HEMK2	Q9Y5N5	482
ARL6IP6	ATP6V1A	P38606	425
ARL6IP6	FAM177A1	Q8N128	374
ARL6IP6	TMED8	Q6PL24	371
ARL6IP6	ANGEL2	Q5VTE6	366
ARL6IP6	MTIF3	Q9H2K0	364
ARL6IP6	MRPS9	P82933	351
ARL6IP6	RNASE13	Q5GAN3	337
ARL6IP6	SDS	P20132	333
ARL6IP6	PLEKHH2	Q8IVE3	328
ARL6IP6	ARL14EP	Q8N8R7	326

IntAct

68 interactions, top by confidence:

A	B	Type	Score
	HMOX1	psi-mi:“MI:0914”(association)	0.740
SLC10A1	ARL6IP6	psi-mi:“MI:0915”(physical association)	0.670
ARL6IP6	AQP6	psi-mi:“MI:0915”(physical association)	0.560
ARL6IP6	GPR61	psi-mi:“MI:0915”(physical association)	0.560
ARL6IP6	CMTM2	psi-mi:“MI:0915”(physical association)	0.560
ARL6IP6	TMEM80	psi-mi:“MI:0915”(physical association)	0.560
AQP6	ARL6IP6	psi-mi:“MI:0915”(physical association)	0.560
EBP	ARL6IP6	psi-mi:“MI:0915”(physical association)	0.560
ARL6IP6	RUSF1	psi-mi:“MI:0915”(physical association)	0.560
TMEM205	ARL6IP6	psi-mi:“MI:0915”(physical association)	0.560
GJA8	ARL6IP6	psi-mi:“MI:0915”(physical association)	0.560
ARL6IP6	TIMMDC1	psi-mi:“MI:0915”(physical association)	0.560
CLRN2	ARL6IP6	psi-mi:“MI:0915”(physical association)	0.560
TMEM86B	ARL6IP6	psi-mi:“MI:0915”(physical association)	0.560
TBXA2R	ARL6IP6	psi-mi:“MI:0915”(physical association)	0.560
MGST3	ARL6IP6	psi-mi:“MI:0915”(physical association)	0.560
SPINT2	UPK3BL1	psi-mi:“MI:0914”(association)	0.530
ARL6IP6	YKT6	psi-mi:“MI:0914”(association)	0.530
AOC3	AOC2	psi-mi:“MI:0914”(association)	0.530
CLEC2B	ASPHD2	psi-mi:“MI:0914”(association)	0.530
ARL6IP6	DRD2	psi-mi:“MI:0915”(physical association)	0.370
Bmpr1a	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
	PLOD2	psi-mi:“MI:0914”(association)	0.350
ARL6IP6	ARPC1B	psi-mi:“MI:0914”(association)	0.350
ARL6IP6	ESYT2	psi-mi:“MI:0914”(association)	0.350
LPAR1	GOSR2	psi-mi:“MI:0914”(association)	0.350

BioGRID (120): YKT6 (Affinity Capture-MS), DUSP3 (Affinity Capture-MS), PNPO (Affinity Capture-MS), BLVRB (Affinity Capture-MS), GSTM1 (Affinity Capture-MS), CBFB (Affinity Capture-MS), PMVK (Affinity Capture-MS), NME2P1 (Affinity Capture-MS), NAA50 (Affinity Capture-MS), UBE2D2 (Affinity Capture-MS), PYGB (Affinity Capture-MS), SNX3 (Affinity Capture-MS), ARL6IP6 (Affinity Capture-MS), PNPO (Affinity Capture-MS), DUSP3 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GRQ0, A0A1B0GSZ0, A0A1B0GVT2, A0A590UK83, A0PK05, A2VDU1, A2VE22, A4QNL6, A5D7B5, A5D992, O43609, O75324, P0DKX4, P29414, P61807, P61808, Q0VFM5, Q15053, Q16655, Q17Q87, Q1L0X2, Q2KIK3, Q2TBG9, Q3MHM8, Q498C7, Q4V921, Q58CU5, Q5RBD8, Q5RF07, Q5RGQ8, Q64448, Q6UWT2, Q80ZU4, Q8BGN6, Q8BUM6, Q8C3K5, Q8C817, Q8K1D8, Q8N6S5, Q91VT8

Diamond homologs: Q3MHM8, Q68FV2, Q8BH07, Q8N6S5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

48 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	38
Likely benign	0
Benign	2

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2500155	NM_152522.7(ARL6IP6):c.373C>T (p.Leu125Phe)	Likely pathogenic

SpliceAI

1580 predictions. Top by Δscore:

Variant	Effect	Δscore
2:152734991:AAG:A	acceptor_gain	1.0000
2:152734992:A:G	acceptor_gain	1.0000
2:152735122:TTC:T	donor_gain	1.0000
2:152735124:CAAGT:C	donor_loss	1.0000
2:152735125:AAG:A	donor_loss	1.0000
2:152735126:AGT:A	donor_loss	1.0000
2:152735127:G:GG	donor_gain	1.0000
2:152735127:GTAAG:G	donor_loss	1.0000
2:152735128:TAA:T	donor_loss	1.0000
2:152735129:AAGTA:A	donor_loss	1.0000
2:152718016:G:T	donor_gain	0.9900
2:152718020:G:GT	donor_gain	0.9900
2:152718043:G:GT	donor_gain	0.9900
2:152718043:G:T	donor_gain	0.9900
2:152720531:A:AG	acceptor_gain	0.9900
2:152720532:G:GG	acceptor_gain	0.9900
2:152720532:GA:G	acceptor_gain	0.9900
2:152720532:GAGTT:G	acceptor_gain	0.9900
2:152727179:A:AG	donor_gain	0.9900
2:152734987:T:A	acceptor_gain	0.9900
2:152734988:GTTAA:G	acceptor_loss	0.9900
2:152734989:TTAA:T	acceptor_loss	0.9900
2:152734990:TAAG:T	acceptor_loss	0.9900
2:152734991:A:AG	acceptor_gain	0.9900
2:152734993:G:A	acceptor_gain	0.9900
2:152734993:G:GC	acceptor_loss	0.9900
2:152735122:TTCAA:T	donor_gain	0.9900
2:152735123:TCA:T	donor_gain	0.9900
2:152735130:AGTAT:A	donor_loss	0.9900
2:152741502:G:GT	donor_gain	0.9900

AlphaMissense

1448 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:152735044:A:C	S169R	0.998
2:152735046:C:A	S169R	0.998
2:152735046:C:G	S169R	0.998
2:152735053:T:A	W172R	0.996
2:152735053:T:C	W172R	0.996
2:152759799:G:C	G214R	0.995
2:152759800:G:A	G214D	0.994
2:152735092:T:C	F185L	0.993
2:152735094:T:A	F185L	0.993
2:152735094:T:G	F185L	0.993
2:152735041:T:C	C168R	0.992
2:152759781:A:C	S208R	0.992
2:152759783:C:A	S208R	0.992
2:152759783:C:G	S208R	0.992
2:152759798:T:A	N213K	0.992
2:152759798:T:G	N213K	0.992
2:152735038:T:C	C167R	0.991
2:152735029:G:A	G164R	0.990
2:152735029:G:C	G164R	0.990
2:152735030:G:A	G164E	0.990
2:152759766:T:C	F203L	0.989
2:152759768:C:A	F203L	0.989
2:152759768:C:G	F203L	0.989
2:152759778:T:C	Y207H	0.988
2:152735072:A:T	D178V	0.987
2:152735074:T:C	S179P	0.987
2:152735065:T:G	Y176D	0.985
2:152759775:G:C	G206R	0.985
2:152735077:T:C	F180L	0.983
2:152735079:T:A	F180L	0.983

dbSNP variants (sampled 300 via entrez): RS1000008360 (2:152715675 C>T), RS1000010697 (2:152752199 T>C), RS1000037764 (2:152760299 C>T), RS1000046795 (2:152720394 T>C), RS1000169314 (2:152745966 T>G), RS1000176764 (2:152760891 G>A), RS1000248823 (2:152720761 G>T), RS1000250326 (2:152752510 T>C), RS1000289351 (2:152725793 T>A), RS1000426507 (2:152716527 T>A,C), RS1000519651 (2:152755348 C>T), RS1000560755 (2:152726195 G>A), RS1000561411 (2:152734480 A>G), RS1000583262 (2:152740474 G>A), RS1000584473 (2:152722181 C>T)

Disease associations

OMIM: gene MIM:616495 | disease phenotypes: MIM:209900

GenCC curated gene-disease

Disease	Classification	Inheritance
cutis marmorata telangiectatica congenita	Limited	Autosomal recessive

Mondo (2): Bardet-Biedl syndrome (MONDO:0015229), cutis marmorata telangiectatica congenita (MONDO:0009055)

Orphanet (1): Bardet-Biedl syndrome (Orphanet:110)

HPO phenotypes

32 total (30 of 32 shown, HPO-id order):

HPO	Term
HP:0000003	Multicystic kidney dysplasia
HP:0000202	Orofacial cleft
HP:0000347	Micrognathia
HP:0000541	Retinal detachment
HP:0000555	Leukocoria
HP:0000821	Hypothyroidism
HP:0000951	Abnormality of the skin
HP:0000965	Cutis marmorata
HP:0000979	Purpura
HP:0001250	Seizure
HP:0001511	Intrauterine growth retardation
HP:0001541	Ascites
HP:0001643	Patent ductus arteriosus
HP:0001770	Toe syndactyly
HP:0001933	Subcutaneous hemorrhage
HP:0002650	Scoliosis
HP:0002814	Abnormality of the lower limb
HP:0002817	Abnormality of the upper limb
HP:0004349	Reduced bone mineral density
HP:0005306	Capillary hemangioma
HP:0006101	Finger syndactyly
HP:0006385	Short lower limbs
HP:0007565	Multiple cafe-au-lait spots
HP:0008065	Aplasia/Hypoplasia of the skin
HP:0100026	Arteriovenous malformation
HP:0100543	Cognitive impairment
HP:0100545	Arterial stenosis
HP:0100555	Asymmetric growth
HP:0100585	Telangiectasia of the skin
HP:0100627	Displacement of the urethral meatus

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST004748_71	Lung cancer	4.000000e-06
GCST005434_30	Pancreatic cancer	3.000000e-07
GCST010002_400	Refractive error	6.000000e-11
GCST012303_5	Recurrent major depressive disorder x sex interaction	5.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0008343	sex interaction measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D020788	Bardet-Biedl Syndrome	C10.228.140.617.200; C11.270.684.624; C16.131.077.245.125; C16.320.184.125
C536226	Cutis marmorata telangiectatica congenita (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects cotreatment, decreases methylation, decreases expression	2
sodium arsenite	affects splicing, decreases expression	2
Benzo(a)pyrene	decreases expression, increases expression	2
Phenylmercuric Acetate	decreases expression, affects cotreatment	2
Valproic Acid	decreases expression, decreases methylation	2
Cyclosporine	decreases expression, increases expression	2
GSK-J4	decreases expression	1
FR900359	decreases phosphorylation	1
triphenyl phosphate	affects expression	1
arsenite	affects binding, decreases reaction	1
perfluorooctanoic acid	decreases expression	1
coumarin	decreases phosphorylation	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Acetaminophen	increases expression	1
Caffeine	increases phosphorylation	1
Calcitriol	affects cotreatment, decreases expression	1
Dietary Carbohydrates	increases expression	1
Estradiol	decreases expression	1
Formaldehyde	decreases expression	1
Testosterone	decreases expression, affects cotreatment	1
Tetrachlorodibenzodioxin	affects expression	1
Urethane	increases expression	1
Aflatoxin B1	decreases methylation	1
Cadmium Chloride	decreases expression	1
Okadaic Acid	decreases expression	1
Copper Sulfate	decreases expression	1

Clinical trials (associated diseases)

17 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03746522	PHASE3	COMPLETED	Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
NCT04966741	PHASE3	COMPLETED	Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
NCT05194124	PHASE3	COMPLETED	Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
NCT03490019	PHASE2	WITHDRAWN	Treatment of Bardet-Biedl-Syndrome With Metformin for Evaluation of a Possible Visual Improvement
NCT00078091	Not specified	TERMINATED	Genetics and Clinical Characteristics of Bardet-Biedl Syndrome
NCT00213811	Not specified	COMPLETED	Bardet-Biedl Syndrome Study: Clinical and Genetic Epidemiology Study in Adults
NCT01401998	Not specified	RECRUITING	ARPKD Database Study
NCT02329210	Not specified	RECRUITING	Clinical Registry Investigating Bardet-Biedl Syndrome
NCT02435940	Not specified	RECRUITING	Inherited Retinal Degenerative Disease Registry
NCT04461444	Not specified	RECRUITING	COhort for Bardet-Bield Syndrome and Alström Syndrome for Translational Research Monocentric Interventional Study
NCT04463316	Not specified	RECRUITING	GROWing Up With Rare GENEtic Syndromes
NCT04874909	Not specified	COMPLETED	Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM)
NCT05183802	Not specified	APPROVED_FOR_MARKETING	An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)
NCT05400278	Not specified	COMPLETED	Characterizing the Genotype and Phenotype in Adults With Bardet-Biedl Syndrome
NCT06239064	Not specified	ACTIVE_NOT_RECRUITING	Early Genetic Identification of Obesity
NCT06615011	Not specified	NOT_YET_RECRUITING	Bardet Beidle Syndrome in a Syrian Adolescent : a Rare Case Report
NCT07602803	Not specified	COMPLETED	The Effect of GLP1 Agonists on Weight Loss in BBS Cohort in the UK